Protagonist Therapeutics, Inc.
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
Last updated:
Abstract:
Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases, are described.
Status:
Grant
Type:
Utility
Filling date:
15 Jul 2016
Issue date:
29 Sep 2020